NR4A1 and breast carcinoma: In this regard, the literature on breast cancer treatment suggests thatadministering adjuvant hormone therapy for five years can reduce disease mortalityby 40% over a 10-year period compared with women who do not use this therapy,particularly in patients who test positive for hormone receptors .30